Accelerator Corp raises $62.8 mln for fourth fund

Accelerator Corp has closed its oversubscribed fourth fund at $62.8 million. The limited partners of Accelerator IV include AbbVie, WuXi PharmaTech, Watson Fund, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC Inc, Pfizer Venture Investments and WRF Capital. The pool will focus on early-stage life science investments. In addition to the fund, Accelerator has named Dr. James P. Sullivan, Dr. Tadataka Yamada and Peter Cheney to its board of directors.


AgBiome picks up $34.5 mln Series B

Research Triangle Park, North Carolina-based AgBiome LLC, an agricultural products developer, has raised $34.5 million in Series B funding. The investors included Bill & Melinda Gates Foundation, the University of Texas Investment Management Company, Pontifax Global Food and Agriculture Technology Fund, Polaris Partners, ARCH Venture Partners, Harris & Harris Group, Innotech Advisers, Monsanto Growth Ventures and Syngenta Ventures.


Voxel8 snaps up $12 mln Series A

Somerville, Massachusetts-based Voxel8, a multi-material 3D electronics printer maker, has raised $12 million in Series A funding. Braemar Energy Ventures and ARCH Venture Partners led the round with participation from Autodesk and In-Q-Tel.


Arivale raises $36 mln

Arivale said Tuesday it raised $36 million in Series B funding led by ARCH Venture Partners and Polaris Partners. Maveron also participated. Seattle-based Arivale is a scientific wellness company.


Aledade snags $30 mln in ARCH Venture-led round

Aledade has raised $30 million in funding. ARCH Venture Partners led the round with participation from Venrock. Based in Bethesda, Maryland, Aledade helps doctors form and operate accountable care organizations. To read the post, visit here.


Denali launches with $217 mln

Denali Therapeutics Inc, a developer of treatments for neurodegenerative diseases, has launched with a $217 million investment commitment. The investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.


Movidius racks up $40 mln

San Mateo, California-based vision processor company Movidius has secured $40 million in funding. Summit Bridge Capital, a joint venture between Atlantic Bridge Capital and WestSummit Capital, led the round with other investors that included ARCH Venture Partners, Sunny Optical Technology Group, AIB Seed Capital Fund, Capital-E, DFJ Esprit and Robert Bosch Venture Capital. In addition to the funding, David Lam of WestSummit Capital has been appointed to Movidius’ board of directors.

Semma Therapeutics nets $44 mln

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has secured $44 million in Series A funding. MPM Capital led the round with participation from Fidelity Biosciences, ARCH Venture Partners and Medtronic. Also, the company has named Stephen Oesterle, senior vice president for medicine and technology at Medtronic, as a board observer.

Kura Oncology snags $60 mln

La Jolla, California-based Kura Oncology Inc, a biopharmaceutical company focused on treating solid tumors and blood cancers, has raised $60 million in a private placement. EcoR1 Capital was the lead investor. Other investors included Fidelity Management & Research Company, ARCH Venture Partners, Tavistock Life Science’s Boxer Capital, Partner Fund Management and Nextech Invest. Leerink Partners LLC was lead placement agent while National Securities Corp and Livingston Securities LLC were co-placement agents for the private placement.


Chiasma snags $70 mln Series E

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.


VC-backed Juno Therapeutics rolls out IPO

Juno Therapeutics has debuted its IPO after pricing its over 11 million shares at $24 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “JUNO.” Morgan Stanley, J.P. Morgan Securities and Goldman Sachs are the lead underwriters. Based in Seattle, Juno is a biotech company focused on developing immunotherapies for cancer. Its backers include Bezos Expeditions, Venrock, ARCH Venture Partners and the Alaska Permanent Fund.


Accelerator Corp raises $51.1 mln for fourth fund

Accelerator Corp. said Tuesday that it has raised $51.1 million in the first close of its fourth fund. The pool’s investors include Alexandria Venture Investments, ARCH Venture Partners, WRF Capital, Eli Lilly, Harris & Harris Group, Johnson & Johnson Development Corp., The Partnership Fund for New York City and Pfizer Venture Investments. Based in Seattle and New York City, Accelerator Corp is a biotech investment firm.

VC-backed Sorbent Therapeutics expands board of directors

Sorbent Therapeutics, a Sunnyvale, Calif.-based biopharmaceutical firm focused on treating cardiovascular and renal diseases, has added Jay Shepard and William D. Waddill to its board of directors. Shepard is an executive partner at Sofinnova Ventures while Waddill is the senior vice president and chief financial officer at Calithera Biosciences. Sorbent’s backers include CMEA Capital, ARCH Venture Partners, Sofinnova Ventures, AgeChem and Novartis Venture Funds.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget